News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • European equity markets slid across major exchanges, many closing at one-month lows as decliners outnumbered advancers.
  • Crude oil jumped sharply, boosting energy stocks and lifting market volatility while gold retreated.
  • UAE pledged €40 billion to invest in Germany, targeting industrial and AI projects and deepening strategic ties.
  • Houthis captured Mocha with alleged tactical and arms support from Iran's Revolutionary Guards, raising Red Sea shipping risk.
  • Alpha Compute secured $47 million in seller financing for a planned 200MW Pennsylvania AI data center campus.
  • A nonprofit sued the Federal Reserve, alleging improper private talks with banks during a capital-rule rewrite and seeking to halt it.

Latest Articles

POET Technologies Reports Second Quarter 2026 Results: Revenue Up 112% Year-Over-Year in Sixth Consecutive Quarter of Sequential Growth

POET Technologies Reports Second Quarter 2026 Results: Revenue Up 112% Year-Over-Year in Sixth Consecutive Quarter of Sequential Growth

POET Technologies Inc. reported a 112% year-over-year revenue increase in Q2 2026, marking its sixth consecutive quarter of sequential growth. The net loss narrowed compared to prior quarters, bolstered by a substantial $400 million financing completed in May, enhancing the company's balance sheet and enabling manufacturing capacity expansion. POET…

Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates

Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates

Parabilis Medicines reported progress in its clinical programs, especially zolucatetide—an investigational direct inhibitor targeting the β-catenin:TCF interaction in multiple Wnt/β-catenin-driven diseases. The company plans to initiate a Phase 3 registrational trial for desmoid tumors in early 2027. Parabilis also announced a major collaboration w…

Legence Reports Second Quarter 2026 Financial Results

Legence Reports Second Quarter 2026 Financial Results

Legence Corp. reported strong second quarter 2026 financial results with record revenues of $1.26 billion, a 111% increase year-over-year, driven by solid organic growth and the Bowers acquisition. Adjusted EBITDA more than doubled to $154.6 million. The company also reported record backlog and awarded contracts totaling $5.67 billion, a 105% incre…

ProQR Announces Second Quarter 2026 Operating and Financial Results

ProQR Announces Second Quarter 2026 Operating and Financial Results

ProQR Therapeutics reported positive Phase 1 target engagement data for AX-0810, marking the first clinical validation of its proprietary Axiomer RNA editing platform targeting NTCP modulation for cholestatic diseases. The company outlined a robust pipeline with upcoming clinical milestones including Phase 1 data for AX-0811, initiation of biliary …

Aebi Schmidt Group Reports 22% Increase in Adjusted EBITDA, 16% Growth in Order Intake and 9% Increase in Net Sales, Reflecting Strong Order Momentum and Over-Proportional Profitability Improvement

Aebi Schmidt Group Reports 22% Increase in Adjusted EBITDA, 16% Growth in Order Intake and 9% Increase in Net Sales, Reflecting Strong Order Momentum and Over-Proportional Profitability Improvement

Aebi Schmidt Group reported a 22% increase in adjusted EBITDA and a 16% growth in order intake for Q2 2026 compared to Q2 2025, alongside a 9% rise in net sales. The company attributes its improved profitability to operational improvements and an expanded market footprint, with strong performance in North America and Europe. Net income turned posit…

Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight

Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight

Nutriband Inc.'s CEO Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit focusing on the company's AVERSA™ abuse-deterrent transdermal technology designed to prevent abuse and accidental exposure of drugs like fentanyl. The technology is covered by broad international patents and aims to improve safety profiles of transdermal drug…

Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer

Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on breast cancer therapies, announced the appointment of Jason O’Byrne as Chief Financial Officer. With a strong background in biotech finance and operations, O’Byrne will support Olema as it approaches key clinical data readouts and prepares for its initial commercial launch…

FactSet Declares Dividend

FactSet Declares Dividend

FactSet has announced a quarterly cash dividend of $1.16 per share, payable on September 17, 2026, to shareholders of record as of August 31, 2026. The company continues to demonstrate commitment to delivering value to shareholders amid its ongoing provision of financial intelligence and AI solutions globally.

Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Pyxis Oncology reported its Q2 2026 financial results and highlighted progress in its MICVO clinical programs targeting recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The company completed a private placement raising approximately $50 million upfront, extending its cash runway into Q2 2027. Updated data from Phase 1 monothe…

Rocket Lab Corporation Announces Progress on Iridium Acquisition: HSR Period Lapses; Form S-4 Filed; FCC Applications Filed; Capital Strategy Underway

Rocket Lab Corporation Announces Progress on Iridium Acquisition: HSR Period Lapses; Form S-4 Filed; FCC Applications Filed; Capital Strategy Underway

Rocket Lab Corporation has reached important milestones in its planned acquisition of Iridium Communications, including the lapse of the Hart-Scott-Rodino antitrust waiting period, filing a Form S-4 registration statement with the SEC, and submitting FCC applications to transfer control of Iridium's licenses. The company is advancing its capital st…

Xanadu and University of Alberta Partner to Accelerate Pharmaceutical Discoveries with Quantum Computing

Xanadu and University of Alberta Partner to Accelerate Pharmaceutical Discoveries with Quantum Computing

Xanadu Quantum Technologies has entered a strategic research partnership with the University of Alberta to develop quantum computing algorithms aimed at accelerating discovery of next-generation photosensitizers for photodynamic cancer therapy. This collaboration seeks to leverage quantum computing to overcome current limitations in drug discovery …

SOLV Energy Reports Second Quarter 2026 Financial Results

SOLV Energy Reports Second Quarter 2026 Financial Results

SOLV Energy, Inc. reported record second quarter 2026 financial results highlighted by a 77% year-over-year revenue increase to $951 million and strong adjusted EBITDA of $117 million. The company closed the acquisition of Roberson Waite Electric, expanding its capabilities in utility substation construction. With a backlog up 44% year-over-year to…